GLG News Analyses of the following article:
CSL says US regulator may block Talecris deal
Published at: www.ft.com
-
Talecris Likely Target for New Entrant into Plasma Therapeutics
May 26, 2009
CSL's recent communication that US regulators were likely to block their acquisition should intensify interest in this growing stable part of the healthcare market. While there may be opportunities for CSL to alter their bid, after a year of deliberation by regulators, a failure to approve the purchase means that a new market entrant may have more success. This opens the path for private equity, a smaller European plasma player, or specialty therapeutics firm.
- Subscribe to Updates
-
Work for one of the world's leading organizations? Get started now.
Get Intelligently Connected
with the world's leading experts
GLG's 850+ Clients Include:
- More than 70% of the world's leading
- mutual funds
- 15 of the leading 20
- global banks
- 9 of the leading 10
- global private equity firms
- 5 of the leading 10
- AmLaw firms
- Fortune 500® Companies
- in nearly every industry sector, including pharmaceuticals, insurance, chemicals, energy and computer software
Gerson Lehrman Group, Inc. connects communities with knowledge through two distinct, yet complementary offerings: GLG Research and G+.